BIRC5 and cancer: The current approaches developed to inhibit survivin in cancer cells can be divided into 5 different classes: (1) survivin-partner protein interaction inhibitors, (2) survivin dimerization inhibitors, (3) survivin gene transcription inhibitors, (4) survivin mRNA inhibitors and (5) survivin immunotherapy.